179 related articles for article (PubMed ID: 2989419)
41. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L
Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of recurrent herpes labialis using a herpes simplex Type-I subunit vaccine. A prospective randomized double-blind multicenter study].
Altmeyer P; Wehrenberg O; Holzmann H; Paul E; Kimmig WK; Wassilew SW; Petres J; Korger G
Hautarzt; 1991 Dec; 42(12):759-63. PubMed ID: 1662671
[TBL] [Abstract][Full Text] [Related]
43. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
[TBL] [Abstract][Full Text] [Related]
44. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
Ashley RL; Crisostomo FM; Doss M; Sekulovich RE; Burke RL; Shaughnessy M; Corey L; Polissar NL; Langenberg AG
J Infect Dis; 1998 Jul; 178(1):1-7. PubMed ID: 9652416
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model.
Chen MH; Zhou Z; Hartley CE; Cowan M; Skinner GR
Vaccine; 1986 Dec; 4(4):249-52. PubMed ID: 3026107
[TBL] [Abstract][Full Text] [Related]
46. Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
Stanberry LR; Burke R; Myers MG
J Infect Dis; 1988 Jan; 157(1):156-63. PubMed ID: 2826603
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.
Bernstein DI; Flechtner JB; McNeil LK; Heineman T; Oliphant T; Tasker S; Wald A; Hetherington S;
Vaccine; 2019 Jun; 37(26):3443-3450. PubMed ID: 31103365
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of serum antibodies to herpes simplex virus types 1 and 2: application of an ELISA technique to 100 cases of anogenital herpes.
Devillechabrolle A; Hugues-Dorin F; Fortier B; Catalan F; Huraux JM
Sex Transm Dis; 1985; 12(1):40-3. PubMed ID: 2988144
[TBL] [Abstract][Full Text] [Related]
49. Antibody response to the herpes simplex virus type 2 AG-4 antigen in guinea pigs with genital herpes infections.
Maragos C; Miller A; May JT
Aust J Exp Biol Med Sci; 1986 Feb; 64 ( Pt 1)():89-95. PubMed ID: 3008691
[TBL] [Abstract][Full Text] [Related]
50. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world.
Nahmias AJ; Lee FK; Beckman-Nahmias S
Scand J Infect Dis Suppl; 1990; 69():19-36. PubMed ID: 2175939
[TBL] [Abstract][Full Text] [Related]
51. Clinical studies with herpes simplex virus type 2 Curtis strain vaccine.
Corey L
Rev Infect Dis; 1991; 13 Suppl 11():S904-5. PubMed ID: 1664125
[No Abstract] [Full Text] [Related]
52. Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins.
Gold D; Ashley R; Solberg G; Abbo H; Corey L
J Infect Dis; 1988 Dec; 158(6):1227-34. PubMed ID: 2848900
[TBL] [Abstract][Full Text] [Related]
53. Protective immunity to genital herpes simplex [correction of simpex] virus type 2 infection is mediated by T-bet.
Svensson A; Nordström I; Sun JB; Eriksson K
J Immunol; 2005 May; 174(10):6266-73. PubMed ID: 15879125
[TBL] [Abstract][Full Text] [Related]
54. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs.
Fotouhi F; Soleimanjahi H; Roostaee MH; Dalimi Asl A
Iran Biomed J; 2008 Apr; 12(2):59-66. PubMed ID: 18506211
[TBL] [Abstract][Full Text] [Related]
55. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
[TBL] [Abstract][Full Text] [Related]
56. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.
McLean CS; Erturk M; Jennings R; Challanain DN; Minson AC; Duncan I; Boursnell ME; Inglis SC
J Infect Dis; 1994 Nov; 170(5):1100-9. PubMed ID: 7963701
[TBL] [Abstract][Full Text] [Related]
57. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
[TBL] [Abstract][Full Text] [Related]
59. Clinical aspects of recurrent oral herpes simplex virus infection.
Glick M
Compend Contin Educ Dent; 2002 Jul; 23(7 Suppl 2):4-8. PubMed ID: 12789980
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
